HOME >> MEDICINE >> NEWS
The Lancet Oncology (TLO)

Billions of dollars are currently being spent on the search for effective drugs that will stop disease before it happens. Advances in genetic testing are providing more opportunities to find out which diseases people are likely to be at risk of developing--but this knowledge has put huge pressure on the medical profession to come up with ways of avoiding disease altogether. This month's leading edge questions the ethical issues involved in chemoprevention and highlights the difficulties in obtaining reliable data from chemoprevention clinical trials. It concludes: "Genetic tests have created a demand for chemoprevention that is threatening to push medicine to its limits; health services could be stretched beyond capacity because they are treating healthy people as well as the sick. To stop this snowball effect it is essential that one simple idea is kept in mind: you can spend all the money in the world on preventive medicine, but when people won't even stop smoking, can it really work?"

STOMACH CANCER - THE LATEST TARGET FOR THE 'MAGIC BULLET'

Gastrointestinal stromal tumours (GISTs) are the most recent cancer type to be targeted by the most effective new drug of recent years--imatinib mesylate. Effective treatment of GISTs has been hindered in the past by their characteristic resistance to conventional chemotherapy and persistent misclassification of these tumours in clinical studies has made pre-2000 data difficult to interpret. However, it is now known that most GISTs contain a mutation in the KIT tyrosine kinase, which means they are an ideal target for imatinib. In their review, Heikki Joensuu and colleagues discuss the recent advances in understanding of these difficult-to-treat tumours and discusses the impact of imatinib on outcome for patients with GISTs. The authors conclude that imatinib "has provided physicians with a well-tolerated and highly effective therapeutic option for a disease for which no systemic therapy existed previously".
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-207-424-4949
Lancet
30-Oct-2002


Page: 1 2

Related medicine news :

1. The Lancet calls for the creation of a world institute for risk evaluation
2. The Lancet calls for creation of Intl Commission on Global Responses to Complex Emergencies
3. Majority of authors retract 1998 Lancet paper-Lancet editor points to implications
4. The Lancet Infectious Diseases (TLID)
5. The Lancet Neurology November press release
6. Lancet readers to join WHO election debate
7. The Lancet Oncology press release
8. The Lancet Neurology October press release
9. The Lancet neurology press release
10. The Lancet Neurology press release
11. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: The Lancet Oncology TLO

(Date:3/6/2015)... The Public Health Accreditation Board ... status to seven more health departments. This week’s decisions ... people can now be assured that their health departments ... of their communities. , Public health departments play a ... people and communities. Across the nation, health departments provide ...
(Date:3/5/2015)... global digital PCR (dPCR) and qPCR market is expected to reach ... 2019. , The global digital PCR (dPCR) and qPCR market is ... 2019. Although the mature markets such as the U.S., Germany, France ... qPCR market the Asia-Pacific region is expected to grow at the ... the digital PCR (dPCR) and qPCR market is driven by factors ...
(Date:3/5/2015)... 05, 2015 A Bakersfield, Calif. state court ... trial awarding the plaintiff Coleen M. Perry a total ... of a TVT-Abbrevo pelvic mesh sling device, manufactured by Ethicon, ... Cartmell , a partner at Wagstaff & Cartmell ... the plaintiff, along with Rich Freese and Tim Goss of ...
(Date:3/5/2015)... New York (PRWEB) March 05, 2015 ... men who allegedly suffered heart attacks, strokes and other ... low testosterone therapies continue to move forward in the ... Northern District of Illinois. According to a Case Management ... forth procedures for the use of master pleadings in ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... this March with extra savings on their ... important of health and nutrition, HomeCEUConnection.com is ... using the promo code, NUTRITION2015 . ... Professionals , HomeCEUConnection.com provides high-quality continuing ...
Breaking Medicine News(10 mins):Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 2Health News:Nearly 113 Million U.S. Residents Now Reaping Benefits of National Public Health Department Accreditation 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 2Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 3Health News:New Research Report by MarketsandMarkets on Digital PCR and qPCR Market Worth $3.97 Billion by 2019 4Health News:Client Wins $5.7 Million in TVT-Abbrevo Verdict against Johnson & Johnson in California State Court 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 2Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 3Health News:Testosterone Lawsuits Move Forward, as Bernstein Liebhard LLP Comments on Most Recent Order Issued in Federal Litigation 4Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2
(Date:3/5/2015)...  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... chronic pain, today announced the appointment of several ... panel of experts will provide support for planning ... the company pipeline of novel investigational therapies to ... range of areas including opioid receptors, addiction, psychiatry, ...
(Date:3/5/2015)... -- LUNGevity Foundation, the nation,s leading lung cancer ... approval of Bristol Myers Squibb,s new immunotherapy drug ... another critical new treatment option to fight lung ... own immune system to fight cancerous cells. Importantly, ... with squamous cell lung cancer, a population for ...
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... the "Japan Pharma Outlook 2015: Year to Watch ... Initiatives" report to their offering. ... from April -2014 (Annexure 1) is a ... - whether generic or innovator. The most of the ...
Breaking Medicine Technology:Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 2Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 3Relmada Therapeutics Names Leading Clinicians and Researchers in Pain Therapy Development to Advisory Roles 4LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 2Japan Pharma Outlook 2015: Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives 3
Cached News: